Are you ready to take the lead and bring the finished dose form Manufacturing to the next level in a fast-growing pharmaceutical company? Do you have an entrepreneurial mindset and the courage to challenge for continuous improvement?
Since the current Director is taking a new step in his career, Xellia Pharmaceuticals is now looking for the right person to take over and further develop the Copenhagen finished dose form factory and organization.
Manage and develop manufacturing organization in a fast-growing company
With direct reference to the VP International Manufacturing, you will have the overall responsibility for the finished dose form production site Copenhagen and its 170 employees. This will include daily execution, compliance and delivery – as well as short- and long-term development of the capabilities.
As leader of the finished dose form leadership team in Copenhagen, you will be responsible for all team and employments issues: lead, motivate and set direction for an organization of highly skilled specialists and operators. You will be a member of the Copenhagen Operational Management team and the International Manufacturing leadership team. It is expected that you contribute actively to the development of both the site supply chain and the International Manufacturing network chain.
- Daily management of finished dose form manufacturing
- Compliance (GMP, environment, safety and health)
- Productivity – deliver as promised and develop manufacturing capabilities
- LEAN and Operational Excellence
- Flexibility in planning and execution
- Development of employees and the organization to fit future needs of the business
- Manage the function according to financial budgets/targets
- Maintain focus on all KPI’s on relevant functional and corporate scorecards
Experienced manufacturing leader with entrepreneurial mindset
You have an education within chemical engineering or similar, and at least 5-10 years of leadership experience in a manufacturing/supply chain environment, including experience from aseptic finished dose form. Furthermore, you have solid understanding of GMP requirements, including US FDA guidelines.
You possess strong people and management skills and are experienced in managing complex initiatives and leading culturally diverse teams, preferably teams/organizations of 100+ people. You are able to influence all levels of employees in a matrix organization and have the ability to operate at a strategic level. You thrive in a fast-paced environment and are able to balance multiple priorities. Moreover, you have an entrepreneurial mindset and courage to challenge for continuous improvement. You have excellent verbal and written communication skills, including presentations, and are fluent in English.
About Xellia Pharmaceuticals
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments. Headquartered in Copenhagen, Denmark, Xellia has global facilities in Europe, North America, and Asia, currently employing over 1700 people. With over 100 years of industry experience in developing last resort treatments for infectious diseases, Xellia is focused on the supply of products which not only save lives, but also improve and enhance patients’ quality of life. Together with us, you can help lead the fight against bacterial infections.
Would you like to learn more?
The recruitment process is carried out in collaboration with the consulting company Compass Human Resources Group. If you want to learn more about this position before submitting your application, please do not hesitate to contact Sr. Research Consultant, Pernille Hemmingsen on mail: Pernille.Hemmingsen@Compasshrg.com.
Please submit your application and CV as soon as possible, if you are interested. Applications will be processed on an ongoing basis. Please note that all enquiries will be handled with confidentiality and that we will reply to the email address from which you send your CV.
Deadline for application: As soon as possible
Company: Xellia Pharmaceuticals